Over the last decade, the development of targeted therapies have held great promise for the treatment of advanced NSCLC, and mutations of the epidermal growth factor receptor (EGFR) gene were identified as a crucial factor that correlated with clinical responsiveness to tyrosine-kinase inhibitors (TKI) [5,6]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.